Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
CD38 expression and function in NK cells. (A) Role of CD38 in the... | Download Scientific Diagram
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
Blood and Hematology - CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
![PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/72ce80f2da87d037624955a597846d530a0c6052/3-Figure1-1.png "PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar")
PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar
Frontiers | Daratumumab for the Treatment of Multiple Myeloma
Expression of CD38 in normal and malignant plasma cells.... | Download Scientific Diagram
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action - Adams - 2019 - Cytometry Part A - Wiley Online Library
![Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.1c00733/asset/images/acs.molpharmaceut.1c00733.social.jpeg_v03 "Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics")
Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes | SpringerLink
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
CD38 - Wikipedia
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma | bioRxiv
ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Double CD38−/CD138− negative multiple myeloma - ScienceDirect
JCM | Free Full-Text | Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
